Related Experiment Video
Updated: May 13, 2026
15:04
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Adjuvant systemic therapies in breast cancer
Leonel F Hernandez-Aya1, Ana M Gonzalez-Angulo
1Division of Hematology/Oncology, Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, MI, USA.
The Surgical Clinics of North America
|March 8, 2013
Summary
Even with early breast cancer (BC) treatment, some women face recurrence. Identifying tumor subtypes helps tailor therapies, improving outcomes and reducing side effects for non-responders.
Area of Science:
- Oncology
- Genomics
- Personalized Medicine
Background:
- Early breast cancer (BC) recurrence affects up to 20% of patients despite loco-regional treatment.
- Adjuvant therapies have significantly improved clinical outcomes for BC patients.
- Tumor subtypes with prognostic value are crucial for treatment stratification.
Purpose of the Study:
- To explore the role of tumor subtypes in predicting treatment response for early breast cancer.
- To advance personalized medicine by identifying predictive biomarkers for BC therapy.
Main Methods:
- Analysis of tumor subtypes in early-stage breast cancer patients.
- Correlation of molecular markers with treatment outcomes and recurrence rates.
- Evaluation of prognostic value of identified tumor subtypes.
Main Results:
- Specific tumor subtypes are associated with higher rates of treatment failure and recurrence.
- Biologic predictive factors can differentiate between responders and non-responders to adjuvant therapies.
- Tailored treatment strategies based on tumor biology show potential for improved efficacy.
Conclusions:
- Identifying specific breast cancer subtypes is essential for predicting treatment response.
- Personalized treatment approaches based on tumor biology can optimize outcomes and minimize toxicity.
- Further research into predictive biomarkers will enhance the management of early-stage breast cancer.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...